Precision Breast Cancer Trial Shows Improved Treatment by Tumor Subtype
Recent results from one of the I-SPY 2.2 study arms, published September 14, 2024 in Nature Medicine, showed that neoadjuvant treatment with the antibody-drug conjugate datopotamab–deruxtecan (Dato-DXd) in combination with the immune checkpoint...
1-Oct-2024 8:00 AM EDT
Add to Favorites